Big Buttons

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

More News

APC Board Chair Joe Navarra, pharmacist Ndidiamaka “Didi” Okpareke, Chief Advocacy Officer Tenille Davis, lobbyist David Pore, and CEO Scott Brunner were in Washington, D.C.’s Rayburn building on June 25, briefing about four dozen House of Representatives healthcare staffers on the practice of pharmacy compounding — and clearing some of the muddied waters.

Didi opened the briefing with an intro to pharmacy compounding, then Scott, Joe, and Tenille talked specifically about GLP-1 compounding, including recent lawsuits against compounders. Most importantly, they explained the regulatory framework for compounding — something that’s often glossed over in mainstream coverage of the practice. 

Keeping in mind the audience, David got into the nitty-gritty with some details about potential bills that could allow pharmacy compounding to step in during drug shortages — a critical issue as the country faces record levels of medications in shortage.

Maintaining this kind of connection with legislators and their staff is how we — APC and its members — protect the practice of pharmacy compounding.

The “…and its members…” part is important, and that’s why you need to join hundreds of APC members in Washington on September 17–18 for Compounders on Capitol Hill. Our voices are louder together!